Hyaluronic acid based next generation bioink for 3D bioprinting of human stem cell derived corneal stromal model with innervation.


Journal

Biofabrication
ISSN: 1758-5090
Titre abrégé: Biofabrication
Pays: England
ID NLM: 101521964

Informations de publication

Date de publication:
29 12 2022
Historique:
received: 15 11 2022
accepted: 13 12 2022
entrez: 29 12 2022
pubmed: 30 12 2022
medline: 31 12 2022
Statut: epublish

Résumé

Corneal transplantation remains gold standard for the treatment of severe cornea diseases, however, scarcity of donor cornea is a serious bottleneck. 3D bioprinting holds tremendous potential for cornea tissue engineering (TE). One of the key technological challenges is to design bioink compositions with ideal printability and cytocompatibility. Photo-crosslinking and ionic crosslinking are often used for the stabilization of 3D bioprinted structures, which can possess limitations on biological functionality of the printed cells. Here, we developed a hyaluronic acid-based dopamine containing bioink using hydrazone crosslinking chemistry for the 3D bioprinting of corneal equivalents. First, the shear thinning property, viscosity, and mechanical stability of the bioink were optimized before extrusion-based 3D bioprinting for the shape fidelity and self-healing property characterizations. Subsequently, human adipose stem cells (hASCs) and hASC-derived corneal stromal keratocytes were used for bioprinting corneal stroma structures and their cell viability, proliferation, microstructure and expression of key proteins (lumican, vimentin, connexin 43,

Identifiants

pubmed: 36579828
doi: 10.1088/1758-5090/acab34
doi:

Substances chimiques

Hyaluronic Acid 9004-61-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Creative Commons Attribution license.

Auteurs

Anni Mörö (A)

Eye Regeneration Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.

Sumanta Samanta (S)

Bioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, University, Tampere 33720, Finland.

Laura Honkamäki (L)

Neuro Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.

Vignesh K Rangasami (VK)

Bioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, University, Tampere 33720, Finland.

Paula Puistola (P)

Eye Regeneration Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.

Maija Kauppila (M)

Eye Regeneration Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.

Susanna Narkilahti (S)

Neuro Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.

Susanna Miettinen (S)

Adult Stem Cell Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.
Research, Development and Innovation Centre, Tampere University Hospital, Tampere 33520, Finland.

Oommen Oommen (O)

Bioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, University, Tampere 33720, Finland.

Heli Skottman (H)

Eye Regeneration Group, Faculty of Medicine and Health Technology, Tampere University, Tampere 33520, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH